Novo Nordisk’s Pipeline Delivers Two Wins as Stock Sinks to Oversold Territory
Novo Nordisk secures rare disease and pediatric diabetes milestones, but shares fall 21% YTD on GLP-1 competition and…
Novo Nordisk’s Rare Disease Breakthrough Fails to Lift Oversold Shares
Novo Nordisk reports positive Phase 3 results for sickle cell drug etavopivat, but shares remain under pressure from…